Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.

  • Visnes, Torkild
  • Benítez-Buelga, Carlos
  • Cázares-Körner, Armando
  • Sanjiv, Kumar
  • Hanna, Bishoy M F
  • Mortusewicz, Oliver
  • Rajagopal, Varshni
  • Albers, Julian J
  • Hagey, Daniel W
  • Bekkhus, Tove
  • Eshtad, Saeed
  • Baquero, Juan Miguel
  • Masuyer, Geoffrey
  • Wallner, Olov
  • Müller, Sarah
  • Pham, Therese
  • Göktürk, Camilla
  • Rasti, Azita
  • Suman, Sharda
  • Raul, Torres-Ruiz
  • Sarno, Antonio
  • Wiita, Elisée
  • Homan, Evert J
  • Karsten, Stella
  • Marimuthu, Karthick
  • Michel, Maurice
  • Koolmeister, Tobias
  • Scobie, Martin
  • Loseva, Olga
  • Almlöf, Ingrid
  • Unterlass, Judith Edda
  • Pettke, Aleksandra
  • Boström, Johan
  • Pandey, Monica
  • Gad, Helge
  • Herr, Patrick
  • Jemth, Ann-Sofie
  • El Andaloussi, Samir
  • Kalderén, Christina
  • Rodriguez-Perales, Sandra
  • Benítez, Javier
  • Krokan, Hans E
  • Altun, Mikael
  • Stenmark, Pål
  • Berglund, Ulrika Warpman
  • Helleday, Thomas
  • Rodriguez Perales, Sandra
  • El Andaloussi, Samir
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.
Repisalud
Publication Artículo científico (JournalArticle)

A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers

  • Baquero, Juan Miguel
  • Benítez-Buelga, Carlos
  • Fernández, Victoria
  • Urioste, Miguel
  • García-Giménez, Jose Luis
  • Perona, Rosario
  • Benitez, Javier
  • Osorio, Ana
Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes involved in the base excision repair (BER) pathway can modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG) might decrease ovarian cancer risk in BRCA2 mutation carriers. In the present study, we validated this finding in a larger series of familial breast and ovarian cancer patients to gain insights into how this UNG variant exerts its protective effect. We found that rs34259 is associated with significant UNG downregulation and with lower levels of DNA damage at telomeres. In addition, we found that this SNP is associated with significantly lower oxidative stress susceptibility and lower uracil accumulation at telomeres in BRCA2 mutation carriers. Our findings help to explain the association of this variant with a lower cancer risk in BRCA2 mutation carriers and highlight the importance of genetic changes in BER pathway genes as modifiers of cancer susceptibility for BRCA1 and BRCA2 mutation carriers.
Repisalud
Publication Artículo científico (JournalArticle)

Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers

  • Benitez-Buelga, Carlos
  • Baquero, Juan Miguel
  • Vaclova, Tereza
  • Fernández, Victoria
  • Martín, Paloma
  • Inglada-Perez, Lucia
  • Urioste, Miguel
  • Osorio, Ana
  • Benítez, Javier
In this report, we have tried to gain molecular insight into a single nucleotide polymorphism (SNP) in the NEIL2 gene previously identified as "cancer risk modifier" for BRCA2 mutation carriers. To that end, we studied the role of this SNP (rs804271) on NEIL2 transcriptional regulation, oxidative DNA damage and genome instability in two independent set of samples: The first one was a series of eighty-six BRCA1 and BRCA2 mutation carriers and eighty non-carrier controls in which we evaluated the effect of the SNP on NEIL2 gene expression and oxidative DNA damage accumulation. The second was a set of twenty lymphoblastoid cell lines (LCLs), thirteen BRCA1 mutation carriers and seven non-carriers control, that were used to analyze the correlation between NEIL2 mRNA and/or protein levels, the oxidative and the double stranded break (DSB) DNA damage levels. Our results suggest that an excessive production of NEIL2 enzyme, associated with the SNP, may have a deleterious effect modifying cancer risk susceptibility in BRCA2 mutation carriers. We hypothesize that due to the SNP impact on NEIL2 transcriptional upregulation, a cascade of events may converge in the accumulation of oxidative DNA damage and its posterior conversion into DSBs for this specific group of patients.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

GRECOS Project (Genotyping Recurrence Risk of Stroke): the use of genetics to predict the vascular recurrence after stroke

  • Fernández-Cadenas, Israel
  • Mendióroz, Maite
  • Giralt, Dolors
  • Nafria, Cristina
  • García, Elena
  • Carrera, Caty
  • Gallego-Fábrega, Cristina
  • Domingues-Montanari, Sophie
  • Delgado, Pilar
  • Ribó, Marc
  • Castellanos, María del Mar
  • Martínez, Sergi
  • Freijo Guerrero, María del Mar
  • Jiménez-Conde, Jordi
  • Rubiera, Marta
  • Álvarez-Sabín, José
  • Molina, Carlos A.
  • Font, María A.
  • Grau Olivares, Marta
  • Palomeras, Ernest
  • Pérez de la Ossa, Natalia
  • Martínez-Zabaleta, Maite
  • Masjuan, Jaime
  • Moniche, Francisco
  • Cánovas, David
  • Piñana, Carlos
  • Purroy, Francisco
  • Cocho, Dolores
  • Navas, Inma
  • Tejero Juste, Carlos
  • Aymerich, Nuria
  • Cullell, Natalia
  • Muiño, Elena
  • Serena, Joaquín
  • Rubio, Francisco
  • Dávalos, Antoni
  • Roquer, Jaume
  • Arenillas, Juan
  • Martí-Fàbregas, Joan
  • Keene, Keith
  • Chen, Wei-Min
  • Worrall, Bradford B.
  • Sale, Michele
  • Arboix, Adriá
  • Krupinski, Jerzy
  • Montaner, Joan
[Abstract] Background and purpose: Vascular recurrence occurs in 11% of patients during the first year after ischemic stroke (IS) or transient ischemic attack. Clinical scores do not predict the whole vascular recurrence risk; therefore, we aimed to find genetic variants associated with recurrence that might improve the clinical predictive models in IS. Methods: We analyzed 256 polymorphisms from 115 candidate genes in 3 patient cohorts comprising 4482 IS or transient ischemic attack patients. The discovery cohort was prospectively recruited and included 1494 patients, 6.2% of them developed a new IS during the first year of follow-up. Replication analysis was performed in 2988 patients using SNPlex or HumanOmni1-Quad technology. We generated a predictive model using Cox regression (GRECOS score [Genotyping Reurrence Risk of Stroke]) and generated risk groups using a classification tree method. Results: The analyses revealed that rs1800801 in the MGP gene (hazard ratio, 1.33; P=9×10-03), a gene related to artery calcification, was associated with new IS during the first year of follow-up. This polymorphism was replicated in a Spanish cohort (n=1.305); however, it was not significantly associated in a North American cohort (n=1.683). The GRECOS score predicted new IS (P=3.2×10-09) and could classify patients, from low risk of stroke recurrence (1.9%) to high risk (12.6%). Moreover, the addition of genetic risk factors to the GRECOS score improves the prediction compared with previous Stroke Prognosis Instrument-II score (P=0.03). Conclusions: The use of genetics could be useful to estimate vascular recurrence risk after IS. Genetic variability in the MGP gene was associated with vascular recurrence in the Spanish population., This study was funded by Marato TV3, by the Spanish stroke research network (INVICTUS-PLUS) and by Generacion project (PI15/01978) Instituto de Salud Carlos III. I. F-C. is supported by the Miguel Servet programme (CP12/03298), Instituto de Salud Carlos III. Several groups participate in the International Stroke Genetics Consortium and the Spanish Stroke Genetics Consortium. The Hospital del Mar is supported by Spain’s Ministry of Health (III FEDER, RD12/0042/0020) Study recruitment and collection of datasets for the VISP trial were supported by a grant (R01 NS34447; PI James Toole) from the National Institute of Neurological Disorders and Stroke (NINDS). GWAS genotyping (U01 HG004438l; PI David Valle), funded by the National Human Genome Research institute and the Genomics and Randomized Trials (GARNET) Network (U01HG00516-03; co-PI Michèle M Sale & Bradford B Worrall), and genetic data cleaning was provided by the GARNET Coordinating Center (U01HG005157; PI Bruce S. Weir).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Automated quantification of cerebral edema following hemispheric infarction, Application of a machine-learning algorithm to evaluate CSF shifts on serial head CTs

  • Chen, Yasheng
  • Dhar, Rajat|||0000-0002-5167-5097
  • Heitsch, Laura
  • Ford, Andria
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Carrera, Caty|||0000-0002-0804-0969
  • Montaner, Joan|||0000-0003-4845-2279
  • Lin, Weili
  • Shen, Dinggang
  • An, Hongyu
  • Lee, Jin-Moo
Although cerebral edema is a major cause of death and deterioration following hemispheric stroke, there remains no validated biomarker that captures the full spectrum of this critical complication. We recently demonstrated that reduction in intracranial cerebrospinal fluid (CSF) volume (∆ CSF) on serial computed tomography (CT) scans provides an accurate measure of cerebral edema severity, which may aid in early triaging of stroke patients for craniectomy. However, application of such a volumetric approach would be too cumbersome to perform manually on serial scans in a real-world setting. We developed and validated an automated technique for CSF segmentation via integration of random forest (RF) based machine learning with geodesic active contour (GAC) segmentation. The proposed RF + GAC approach was compared to conventional Hounsfield Unit (HU) thresholding and RF segmentation methods using Dice similarity coefficient (DSC) and the correlation of volumetric measurements, with manual delineation serving as the ground truth. CSF spaces were outlined on scans performed at baseline (< 6 h after stroke onset) and early follow-up (FU) (closest to 24 h) in 38 acute ischemic stroke patients. RF performed significantly better than optimized HU thresholding (p < 10 - 4 in baseline and p < 10 - 5 in FU) and RF + GAC performed significantly better than RF (p < 10 - 3 in baseline and p < 10 - 5 in FU). Pearson correlation coefficients between the automatically detected ∆ CSF and the ground truth were r = 0.178 (p = 0.285), r = 0.876 (p < 10 - 6) and r = 0.879 (p < 10 - 6) for thresholding, RF and RF + GAC, respectively, with a slope closer to the line of identity in RF + GAC. When we applied the algorithm trained from images of one stroke center to segment CTs from another center, similar findings held. In conclusion, we have developed and validated an accurate automated approach to segment CSF and calculate its shifts on serial CT scans. This algorithm will allow us to efficiently and accurately measure the evolution of cerebral edema in future studies including large multi-site patient populations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GRECOS project (Genotyping Recurrence Risk of Stroke). The use of genetics to predict the vascular recurrence after stroke

  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Mendioroz, Maite|||0000-0002-4179-5781
  • Giralt, Dolors
  • Nafría, Cristina
  • Garcia, Elena
  • Carrera, Caty|||0000-0002-0804-0969
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Domingues-Montanari, Sophie
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Ribo, Marc|||0000-0001-9242-043X
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Martínez, Sergi
  • Freijo, Mari Mar
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Rubiera, Marta
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Font, Maria Angels
  • Grau Olivares, Marta
  • Palomeras, Ernest|||0000-0002-0724-8653
  • Pérez de la Ossa, Natalia|||0000-0002-6063-211X
  • Martinez Zabaleta, Maite
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Moniche, Francisco|||0000-0001-8613-2909
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Piñana, Carlos|||0000-0001-7316-6202
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cocho, Dolores
  • Navas, Inmaculada
  • Tejero, Carlos
  • Aymerich, Nuria
  • Cullell, Natalia|||0000-0001-5118-1014
  • Muiño, Elena|||0000-0001-5839-7328
  • Serena, Joaquín|||0000-0002-4478-7744
  • Rubio, Francisco
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Keene, Keith
  • Chen, Wei-Min
  • Worrall, Bradford
  • Sale, Michele
  • Arboix, Adrià|||0000-0002-8512-7881
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Montaner, Joan|||0000-0003-4845-2279
Background and Purpose-Vascular recurrence occurs in 11% of patients during the first year after ischemic stroke (IS) or transient ischemic attack (TIA). Clinical scores do not predict the whole vascular recurrence risk, therefore we aimed to find genetic variants associated with recurrence that might improve the clinical predictive mode is in IS. Methods-We analyzed 256 polymorphisms from 115 candidate genes in three patient cohorts comprising 4,482 IS or TIA patients. The discovery cohort was prospectively recruited and included 1,494 patients, 6.2% of them developed a new IS during the first year of follow-up. Replication analysis was performed in 2,988 patients using SNPlex or HumanOmni1-Quad technology. We generated a predictive model using Cox regression (GRECOS score), and generated risk groups using a classification tree method. Results-The analyses revealed that rs1800801 in the MGP gene (HR: 1.33, p= 9×10-03), a gene related to artery calcification, was associated with new IS during the first year of follow-up. This polymorphism was replicated in a Spanish cohort (n=1.305), however it was not significantly associated in a North American cohort (n=1.683). The GRECOS score predicted new IS (p=3.2×10-09) and could classify patients, from low risk of stroke recurrence (1.9%) to high risk (12.6%). Moreover, the addition of genetic risk factors to the GRECOS score improves the prediction compared to previous SPI-II score (p=0.03). Conclusions-The use of genetics could be useful to estimate vascular recurrence risk after IS. Genetic variability in the MGP gene was associated with vascular recurrence in the Spanish population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres, Nuria
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). VKAs: Warfarin, acenocoumarol, fluindione and phenprocoumon have long been used, but their interindividual variability and narrow therapeutic/safety ratio makes their dosage difficult. GWAs have been useful in finding genetic variants associated with VKAs response. The main genes involved in VKAs pharmacogenetics are: VKORC1, CYP2C19 and CYP4F2. Variants in these genes have been included in pharmacogenetic algorithms to predict the VKAs dose individually in each patient depending on their genotype and clinical variables. DOACs: Dabigatran, apixaban, rivaroxaban and edoxaban have been approved for patients with AF. They have stable pharmacokinetics and do not require routine blood checks, thus avoiding most of the drawbacks of VKAs. Except for a GWAs performed in patients treated with dabigatran, there is no Genome Wide pharmacogenomics data for DOACs. Pharmacogenomics could be useful to predict the better clinical response and avoid adverse events in patients treated with anticoagulants, identifying the most appropriate anticoagulant drug for each patient. Current pharmacogenomics data show that the polymorphisms affecting VKAs or DOACs are different, concluding that personalized medicine based on pharmacogenomics could be possible. However, more studies are required to implement personalized medicine in clinical practice with OA and based on pharmacogenetics of DOACs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress

  • Visnes, Torkild|||0000-0003-1047-988X
  • Benítez-Buelga, Carlos
  • Cázares-Körner, A.
  • Sanjiv, K.
  • Hanna, Bishoy
  • Mortusewicz, O.
  • Rajagopal, Veera M.|||0000-0002-5236-168X
  • Albers, J. J.
  • Hagey, D. W.
  • Bekkhus, T.
  • Eshtad, S.
  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Masuyer, G.
  • Wallner, Olov|||0000-0002-6481-237X
  • Müller, S.
  • Pham, T.
  • Göktürk, C.
  • Rasti, A.
  • Suman, S.
  • Torres, Raul|||0000-0001-9606-0398
  • Sarno, A.
  • Wiita, E.
  • Homan, E. J.
  • Karsten, S.
  • Marimuthu, K.
  • Michel, M.
  • Koolmeister, T.
  • Scobie, M.
  • Loseva, O.
  • Almlöf, I.
  • Unterlass, J. E.
  • Pettke, A.
  • Boström, J.
  • Pandey, M.
  • Gad, H.
  • Herr, P.
  • Jemth, A. S.
  • El Andaloussi, S.
  • Kalderén, C.
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Benítez, J.
  • Krokan, H. E.
  • Altun, M.
  • Stenmark, P.
  • Berglund, U. W.
  • Helleday, Thomas|||0000-0002-7384-092X
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Castillo, José
  • Freijo, Marimar
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Obach, Víctor|||0000-0002-0518-1053
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Ribo, Marc|||0000-0001-9242-043X
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Diaz-Navarro, Rosa
  • Vives-Bauza, Cristòfol
  • Serrano-Heras, Gemma|||0000-0001-9368-4832
  • Segura, Tomás|||0000-0003-3625-0987
  • Ibañez, Laura
  • Heitsch, Laura
  • Delgado, Pilar
  • Dhar, Rajat|||0000-0002-5167-5097
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Blay, Natalia|||0000-0002-7160-8529
  • Sumoy, Lauro|||0000-0003-0005-4618
  • de Cid, Rafael|||0000-0003-3579-6777
  • Montaner, Joan|||0000-0003-4845-2279
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lee, Jim-Moo
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background: Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification. Methods: Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort. Results: We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension. Conclusion: The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.